— A WORLD CLASS TEAM. A POWERFUL BLEND OF PERSPECTIVES. —
STRENGTH AND EXPERTISE IN
HEALTHCARE INVESTMENT BANKING
Jeff brings over 30 years of investment banking and corporate advisory experience to WaveEdge Capital. He started his career in 1980 at Morgan Stanley and later moved to Goldman Sachs, all in NYC. He has participated in over $5B in investment banking transactions and has extensive knowledge of the capital raising and M&A process. In addition, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures.
Jeff holds an MBA from Dartmouth’s Amos Tuck School of Business Administration (Tuck Scholar) and a BA in Economics from Dartmouth College. He later received an MA in Comparative Philosophy and Religion on the west coast. Jeff was recently named to the Connected Health Conference Advisory Board 2017, a merger of the Partners Connected Health Symposium and the Personal Connected Health Alliance’s Connected Health Conference (formerly the mHealth Summit). Jeff is an avid skier and cyclist and is passionate about philosophy, the history of ideas, poker theory, and global economic analysis. (FINRA 7, 24, 63, 79, 99)
John advises life sciences companies on M&A, licensing and financial strategy. He also frequently speaks on topics in valuation, deal term benchmarking, and strategy.
Prior to joining WaveEdge, John was a Managing Director at Woodside Capital Partners, a boutique investment bank. Previously, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small to mid-cap biopharmaceutical, medical device, and diagnostics companies on M&A, licensing strategies, portfolio management, valuation and strategic direction. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.
Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised many of the top 20 pharmaceutical and medical device companies, as well as Fortune 500 companies in other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 79, 63)
30+ years in corporate strategy, operations, supply chain, shared services platforms.
Strategy and consulting in healthcare leading to vertical integration and synergies
President & CEO, Daimler Commercial Vehicles – International 2B revenue unit
Leadership roles, Penske Automotive Group, Nissan and Meritor
MS, Management of Information Systems, UCLA
MS, Systems Analysis, and BS, Science & Technology, CAECE University, Buenos Aires, Argentina
Gail Gannon, MSPH
Gail Gannon, MSPH
Gail combines experience in digital health with a strong therapeutics background. Her years of work to include mentoring budding entrepreneurs and graduate students (MD/PhDs) California Life Sciences Association (CLSA), U.S. Market Access Center (US•MAC), UCSF Lean Launchpad, Stanford SPARK, and the Astia Life Sciences Advisory Board give Gail broad knowledge of the regional, national and international players in the digital health and therapeutic space. Gail is particularly good at helping early and mid-stage companies figure out and articulate their business model, often helping founders pivot to more lucrative markets they had not considered.
Gail received her Masters in Social and Behavioral Sciences from the Harvard T.H. Chan School of Public Health, and earned a Biotechnology Certificate with honors from the University of California, Santa Cruz. She’s held clinical management positions at Stanford and UCSF, and consults on clinical process improvements and technology applications to university hospitals and physician groups.
Gordon co-founded Alexza, Maxygen and SurroMed, and was the CEO of Affymax and Alavita. Gordon has over 30 years’ experience managing the discovery and development of pharmaceuticals and novel life science technologies. He also leads University of California’s Silicon Valley Initiative. Gordon started his career as a tenured Professor of Pharmacology at the Stanford University School of Medicine.
Allen supports all aspects of strategic partnerships, capital raising, and M&A activity for the Firm’s clients. Prior to joining WaveEdge Capital, Allen worked as a Research Associate at iPierian, where he investigated and developed cellular models for neurodegenerative disorders. Allen performed undergraduate research in the field of protein engineering at the University of California at Davis, where he received a BS in Biotechnology. (FINRA 63, 79)
Kevin is an Analyst at WaveEdge Capital, where he supports all aspects of strategic partnerships, capital raising, and M&A activity for the Firm’s clients.
Kevin brings over 3 years of experience in the venture capital space. Prior to joining WaveEdge Capital, Kevin worked as an Investment Analyst at Fenox Venture Capital, a Silicon Valley-based VC, where he helped raise capital, conducted deep due diligence on hundreds of start-ups, and contributed in the investment decision of companies ranging from HealthIT, 3D printing, robotics and FinTech. Prior to Fenox, Kevin worked as a Finance Intern at Intellectual Ventures, a Seattle-based VC and one of the top-ten owners of US patents, where he worked closely with senior management to develop investor pitch decks, perform market research and analyze, benchmark and report fund metrics. Previously, he was an early employee and key contributor at PitchBook Data, a leading private equity and venture capital research firm, where he had the lead role in discovering new data sources that enabled the valuation of VC-backed companies.
Kevin holds a BA in Finance from University of Washington, Michael G. Foster School of Business.
Frank brings deep scientific diligence expertise linked with a thoughtful approach to business. Previously, Frank was a Managing Director at Woodside Capital Partners, a boutique investment bank headquartered in Silicon Valley. During the 12 years prior to joining Woodside, Frank was highly regarded for his due diligence work for biotechnology, pharmaceutical, medical device, diagnostic, and bioinformatics companies on behalf of top tier venture and private equity firms. He reviewed dozens of deals from seed to mezzanine stage, bringing his unique perspective regarding innovation, scientific rigor, clinical utility, and commercial potential to bear.
Frank is also an expert in pattern recognition and artificial neural systems. He developed artificial vision and face recognition systems at Lawrence Livermore National Laboratory. Frank applied his pattern recognition skills to become an early innovator in the genomics revolution, leading the bioinformatics team for the Human Genome Project at Lawrence Berkeley National Lab. He helped launch three biotech startups and headed a discovery group at Parke-Davis (now part of Pfizer). He was a co-founder and CSO of Centient Consulting, a management consulting firm working with startups and investors. In that capacity he served as President and acting CEO for two biotech businesses. He has worked at all levels in the clinical trial process, from Phase I to Phase IV after-market studies.
Frank holds an MD from the University of Ghent Medical School in Belgium and a PhD in Neuroscience from the University of California at Berkeley, where he was a Fulbright Scholar. He was a lecturer in the Medical School and a tutor at the UC Berkeley-UCSF Joint Medical Program. Frank is an avid triathlete who has competed in 11 Ironman races and 3 Boston marathons. He is on the Board of the Brain Aneurysm Foundation and coaches the bicycling team for the Juvenile Diabetes Research Foundation. (FINRA 63,79)
Donna leads the Firm’s Digital Health initiative, with a unique background, combining 10 years in marketing, sales and business management in the semiconductor industry with 10 years of execution and strategy development for design and manufacturing services companies serving the medical device and healthcare markets.
Donna was the founder and lead strategist at The Arden Group, a strategy and business development consultancy focused on helping companies take advantage of the tectonic shifts in healthcare created by the powerful trends of connectedness, personalization and globalization.
Donna was Healthcare Strategy Director at Jabil, where she created and developed and executed on the Company’s healthcare strategy. Prior to Jabil, Donna developed and directed the strategic planning and technology roadmap at Flextronics. In both roles, Donna directed healthcare investments based on strategic and financial analysis combined with creative business planning.
Donna is also a free-lance journalist and has published numerous articles on digital healthcare and healthcare strategy. Donna holds a BS in Electrical Engineering from Boston University. (FINRA 63,79)
Yasuhiro (Yas) Hashimoto is the former Founder, President and CEO of MediBIC Group, a leading public biotechnology company in Japan specializing in biomarker discovery and pharmacogenomics. He also established Asia Private Equity Capital, MediBIC’s Investment division, which specialized in Asian biotech companies. Previously, Yas was Founder and CEO of Genetic Lab in Japan (subsequently acquired by Transgenic Inc.) and a Department Head at Nippon Glaxo. Yas has also been a board member of Strand Genomics in India and prior to joining Glaxo, an executive at Syntex. Earlier in his career, Yas was an Associate Professor at the University of Pennsylvania Medical School, among other faculty appointments.
Yas has deep scientific expertise in inflammation and immunology, molecular analysis, diagnostics, regenerative medicine, stem cells, and oncology. He has a deep network of senior relationships in big pharma, biotechs, other R&D based companies, VCs, and financial firms in Japan, Korea, China, Singapore and India. He is the recipient of numerous awards and fellowships. Yas received his medical degree at Osaka University Medical School.
Stuart Hwang, PhD
Stuart Hwang, PhD
Stuart has 10 years in pharmaceutical business development with a cumulative transaction value in excess of $1B. He has led corporate development efforts to establish strategic alliances, in/out licensing, and M&A. Earlier, he was a corporate development and licensing consultant for biotech companies, led business development at Astex (ASTX; acquired by Otsuka) partnerships (GSK R&D collab.), licensing, and M&A (Astex Tx). Prior to that he held leadership roles in business development and commercialization at Perlegen and Agilent.
He has 20 years experience leading drug and diagnostic R&D teams at SuperGen, Cor Therapeutics, Millennium, Celera, Agilent, and at UCSF/LBNL driving 6 INDs and supported the development of 3 marketed drugs. He developed deep sequencing and genome partitioning algorithms at Celera Genomics and at Agilent, several first whole genome arrays (rat, stem cells, & important agricultural genomes). He also discovered a breast cancer gene that is part of a widely used breast cancer panel for early diagnosis.
Stuart is an inventor on several patents, authored 20 journal articles, and presented numerous papers at global scientific & business meetings. He received a BA in Biology with High Honors, UCSC, and PhD in Endocrinology at UC Berkeley, Cancer Research Lab under a NCI fellowship & post-doctoral work at UCSF & the Lawrence Berkeley National Laboratory as a Distinguished Human Genome Postdoctoral Fellow (DOE).
Alan’s passion is helping evolving healthcare organizations achieve milestones that benefit from the transition to value-based medicine. With more than twenty-five years of healthcare experience, he understands both the opportunities and challenges related to this changing marketplace.
Alan has served in leadership roles as an entrepreneur, investor, senior team member and advisor to healthcare companies at all stages of growth. His focus is on segments that span hospitals and health systems, commercial and self-insured payers, and consumer solutions that reduce “out-of-pocket” costs. This includes revenue cycle, supply chain, physician alignment, and patient engagement solutions along with assorted medical devices, diagnostics, and services.
Currently Alan consults with healthcare organizations facing strategic, operational and/or financial challenges.
Alan was Managing Director, Corporate Development, at The Advisory Board Company (NASDAQ: ABCO) where he led four transactions creating over $138M in market value. Previously, he was a Partner in INVESCO Private Capital and Montgomery Medical Ventures. Earlier in his career, Alan was Founder and CEO of a health services company. Here he achieved profitability during first-year operations from a $420K seed investment.
Alan holds an MBA from the Yale School of Management and earned his BA from the University of California, Berkeley.
Joseph C. Kvedar, MD, is creating a new model of healthcare delivery by leveraging personal connected health technologies and remote monitoring tools to better manage chronic conditions, maintain health and wellness, and improve adherence, engagement and clinical outcomes. He is the author of The Internet of Healthy Things, describing how everyday objects will capture and use real-time biometric data to ultimately change behavior to improve our health. Dr. Kvedar created Wellocracy, a leading source of impartial, easy-to-understand information to encourage the sustained use of personal “self-health” technologies.
He is internationally recognized for his leadership and vision in the field of connected health, and has authored over 100 publications on the subject; the popular cHealth Blog provides his insights and vision for connected health. Dr. Kvedar serves as a strategic advisor at Qualcomm Life, Puretech Ventures and BD Technologies, and is a mentor at Blueprint Health, providing guidance and insight to developing companies. Dr. Kvedar is also a mentor at the Harvard Innovation Lab and serves as a judge for its President’s Challenge for Entrepreneurship.
David Maltz is the Founder and Principal of Intervalent, an independent consultancy focused on product development and innovation strategy for consumer-facing medical devices. With over 20 years in product design & development, the last 15 of those focused exclusively on life sciences, David is a design thinker, innovation catalyst, and product realization expert with “T-shaped” skillset, combining deep product design and development experience with broad business and management aptitude. He is passionate about developing sophisticated technologies into human-centric products.
David has extensive inhaled drug-delivery experience with Nektar Therapeutics and Novartis Pharmaceuticals Corporation, where he oversaw the design, development and manufacturing of several novel pulmonary drug delivery systems for a total of 12 years. Before Nektar, David held technical and leadership positions at Game Ready and Bridge Design.
At Novartis, David was deeply involved in efforts to leverage information technology to improve both clinical study operations (Trials of the Future) and patient outcomes (Digital Medicines), and oversaw the development of all Mobile Medical Apps within Novartis that are regulated as medical devices. He continues to be interested in the harmonious integration of medical devices and information technology, including digital biomarkers.
David holds BSE, MSE, and MBA degrees from Stanford University, has numerous patents pending and awarded, and is an author of several publications in both inhaled drug delivery and the medical device development process.
David Lee Scher, MD
David Lee Scher, MD
David has over 30 years of experience in healthcare as a practicing cardiac electrophysiologist, clinical trials investigator, IRB chair, and Medicare Carrier Committee member. He was a pioneer adopter and thought leader of remote patient monitoring. David founded DLS Healthcare Consulting, LLC specializing in advising digital health technology vendors, their partners, investors and clients. He became part of the mobile health expert group of HIMSS and his blog, The Digital Health Corner, is considered one of the industry’s best. David’s expertise in the healthcare and digital health technology sectors adds to WaveEdge’ already solid commitment to developing and investing in digital health.
David received his BA from Washington University in St Louis, an MD with Honors from the University of Bologna, Italy, and completed his Fellowships in Cardiology and Cardiac Electrophysiology at Presbyterian-University of Pennsylvania Medical Center. He is the author of many papers and book chapters and lectures around the world on digital health technology.
Peter is a pharmaceutical executive with more than 25 years of drug development experience. He is Founder and CEO of OCTAVE Pharma, a development stage, start-up biopharmaceutical company.
His past appointment was President and Director of Vivus Inc, a public pharmaceutical company developing and commercializing therapies in obesity, sleep apnea, diabetes, and sexual dysfunction. Under his leadership, he obtained four consecutive drug approvals by successfully building and developing Vivus’s R&D product pipeline. He also helped raise over $500M in corporate financing at his last company. His key achievements during his tenure at VIVUS were; FDA approval for Qsymia-first combination and most effective obesity treatment, FDA & EMA approvals for Stendra-the fastest acting PDE5 inhibitor for ED, FDA approval for Evamist-first transdermal spray for menopausal symptoms. Prior to VIVUS, he held various research and development roles at Genentech and XOMA corporation in the areas of inflammation, infectious disease and critical care medicine.
Peter holds a B.S. in Chemistry from University of California Berkeley and an M.B.A. from Santa Clara University. He has multiple patents approved and pending to his name.